Tolvaptan and Coreg drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tolvaptan (tolvaptan) and Coreg (carvedilol). Common drug interactions include blood iron decreased among females and cardiac failure congestive among males.

The phase IV clinical study analyzes what interactions people have when they take Tolvaptan and Coreg. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Tolvaptan?

Tolvaptan has active ingredients of tolvaptan. eHealthMe is studying from 5,685 Tolvaptan users. Check the latest studies of Tolvaptan.

What is Coreg?

Coreg has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 49,584 Coreg users. Check the latest studies of Coreg.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

30 people who take Tolvaptan and Coreg together, and have interactions are studied.

What are the common drug interactions of Tolvaptan and Coreg, by gender? *:

female:

Blood iron decreased
Blood parathyroid hormone increased
Blood uric acid increased
Cardiac arrest
Constipation
Cystatin c increased
Decreased appetite
Discomfort
Early satiety (feeling full before completing a normal sized meal)
Gastric varices

male:

Cardiac failure congestive
Hypotension (abnormally low blood pressure)
Multiple injuries
Surgery
Blood chloride decreased
Blood creatinine decreased
Blood glucose increased
Blood potassium increased
Blood sodium decreased
Carbon dioxide decreased

What are the common drug interactions of Tolvaptan and Coreg, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Anion gap increased
Blood albumin decreased
Blood calcium increased
Blood chloride increased
Blood creatinine increased
Blood osmolarity increased
Blood potassium increased
Blood urea increased
Blood uric acid increased
Carbon dioxide decreased

40-49:

Abdominal distension
Blood creatinine increased
Blood potassium decreased
Cardiac failure congestive
Hepatomegaly (abnormal enlargement of the liver)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Oedema (fluid collection in tissue)

50-59:

Muscle atrophy (a decrease in the mass of the muscle)
Myocarditis (inflammation of heart muscle myocardium)
Osteoporosis postmenopausal (weak bone with possibility to break after stopped menstrual cycles)
Platelet count decreased
Pleural effusion (water on the lungs)
Portal hypertension (increase in the blood pressure within a system of veins called the portal venous system)
Procedural haemorrhage (procedural bleeding)
Pulmonary congestion (congestion in the lungs)
Pulmonary valve disease
Pulseless electrical activity

60+:

Cardiac failure congestive
Hypotension (abnormally low blood pressure)
Renal failure (kidney dysfunction)
Dyspnoea (difficult or laboured respiration)
Injury
Cardiomegaly (increased size of heart than normal)
Cough
Renal failure acute (rapid kidney dysfunction)
Alanine aminotransferase increased
Anaemia (lack of blood)

What are the existing conditions these people have? *

Cardiac Failure Congestive: 14 people, 46.67%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 4 people, 13.33%
Blood Sodium Decreased: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tolvaptan and Coreg?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously